Indevus Pharmaceuticals, Inc. submits new drug to FDA
Shares of Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) are edging higher in pre-market trading after the specialty pharmaceutical company reported it has submitted a new drug application to the U.S. Food and Drug Administration for the approval of NEBIDO intramuscular injection.
NEBIDO is a long-acting testosterone therapy intended to treat male patients with primary and secondary hypogonadism.
Shares of Indevus gained $0.25, or 3.52%, to $7.35 in pre-market trading.
